LABORATORY FEATURES OF COVID-19 ASSOCIATED CARDIOVASCULAR SYNDROME

This article will study the features of laboratory findings in patients with cardiovascular complications associated with COVID-19 infection. A prospective study was carried out. The main group (n=150) consisted of patients with changes in the cardiovascular system related to COVID-19, i.e., newly diagnosed CV pathology, and patients with exacerbation of cardiac pathology against the background of COVID-19. The comparison group (n=154) included patients with COVID-19 without any significant concomitant cardiac pathology. The average age of patients in the main group was 67.7 years (from 47 to 86 years) and in the comparison group - 66.1 years (from 48 to 88 years). The study groups were representative and did not differ statistically, like COVID-19 symptoms and the degree of lung involvement. It was found that at the initial stages and in the dynamics of COVID-19 in combination with CVS pathology, it is characterized by a statistically significant difference in the levels of D-dimer (p<0.001), ferritin (p<0.001), C-reactive protein (p<0.05), sedimentation rate erythrocytes (p<0.05), procalcitonin (p<0.001), leukocyte indices (neutrophil-lymphocyte index (p<0.001), neutrophil nuclear shift index (p<0.01) and leukocyte shift (p<0.001)). The COVID-19-associated cardiovascular syndrome is characterized by a more pronounced hypercoagulable syndrome, inflammatory tissue damage, and an immune-inflammatory response with a statistically significant difference in specific pro-inflammatory markers and leukocyte indices.

Hali tarjima qilinmagan